Patient survival and response. (A) PFS and OS after starting ibrutinib. The median for PFS was not reached, and the median OS was 69.1 months. (B) Swimmers plot with outcomes for each individual patient. Gray shading shows time before the first formal response assessment. Before that, patients were assessable for disease progression and survival but not remission. Patient 1 continued to receive treatment despite PD in the marrow because of the clinical benefit. Patients who discontinued therapy without disease progression discontinued for either AEs or death. Note that there is no patient 24 or patient 38 because those patients were found to be ineligible at screening and they received a study number but did not start study treatment. C, classic; V, variant.